TELA
TELA Bio, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$0.97
−0.48%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.95
From 52W high−36.58%
Volume56905.00
Market cap$43.80M
P/E (TTM)—
P/S (TTM)0.5x
Div yield—
Key dataOct 19, 2026
Open
$0.95
From 52W high
−36.58%
Volume
56905.00
Market cap
$43.80M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.1x
P/E (TTM)
—
RSI (14)
39.8
MomentumView details →
1D Return
−0.48%
YTD Return
−20.33%
SummaryUpdated Jun 1, 2026
TELA Bio, Inc. (NASDAQ:TELA) is a commercial-stage medical technology company founded in 2012 and headquartered in Malvern, Pennsylvania. The company went public in November 2019 and specializes in developing and commercializing soft-tissue reconstruction solutions for hernia repair and plastic surgery applications. TELA Bio focuses on providing alternatives to traditional synthetic mesh products by offering reinforced tissue matrices derived from natural ovine (sheep) tissue combined with synthetic materials to optimize patient outcomes while preserving anatomical integrity.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration granted 510(k) clearance to TELA Bio's Liora Monofilament Scaffold for soft tissue reinforcement.15d agoTELA Bio, Inc. obtained a limited consent from Perceptive Credit Holdings V, LP and the consenting lenders waiving the minimum revenue covenant under its credit agreement for the fiscal quarters ending on or about September 30, 2026 and December 31, 2026.20d agoTELA Bio announced a strategic cost reduction initiative to reduce annual operating expenses by $17.0 million or 18%.50d ago